Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Brighton, Australia Clinical Trials

A listing of Brighton, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (636) clinical trials

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK, and PD study of avelumab in combination with other immune modulators in adult patients with locally advanced or metastatic solid tumors (eg, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple-negative ...

Phase

0.21 miles

Learn More »

Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents

An observational study investigating the utilisation and effectiveness of originator and biosimilar anti-TNF agents in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.

Phase N/A

0.21 miles

Learn More »

ReActiv8 for Chronic Low Back Pain

The purpose of this Clinical Study is to investigate the effect of electrical stimulation for chronic low back pain.

Phase N/A

1.9 miles

Learn More »

Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

Multicenter, open-label, phase 1 study of Cu(II)ATSM administered orally to patients wit amyotrophic lateral sclerosis/motor neuron disease. The study will be conducted in three phases. In the first two phases, dose cohorts of six patients each will participate in a single dose pharmacokinetic study followed by a 28-day repeated daily ...

Phase

2.21 miles

Learn More »

A Long-term Safety Study of Intranasal Esketamine in Treatment-resistant Depression

This is an open-label (the researchers and participants know the treatment the participant is receiving) long-term extension study. The study will consist of 2 open-label Phases: 4-week Induction phase (if applicable) and Open-Label Optimization/Maintenance phase (variable). Participants will enter the study Induction Phase from ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ...

Phase

2.21 miles

Learn More »

Cardiovascular Longitudinal Evaluation & Assessment of Risk (CLEAR) Study

Design: Longitudinal cohort study Objectives Establish a database of cardiovascular risk factors Correlate with long-term cardiovascular outcomes Assign suitable volunteers to appropriate clinical studies

Phase N/A

2.21 miles

Learn More »

An Open-Label Crenezumab Study in Patients With Alzheimer's Disease

In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg IV Q4W will be offered to all patients who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in patients on long-term crenezumab treatment and to investigate the effect of crenezumab on ...

Phase

2.21 miles

Learn More »

Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected Individuals

The co-EC study aims to to enhance HCV care and treatment among HIV-infected individuals through a predominantly nurse-led model of care in primary care as well as hospital settings. It involves: A nurse-led model of care in primary health care to increase access to PBS HCV treatment with interferon-free HCV ...

Phase N/A

2.93 miles

Learn More »

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect)-controlled, event-driven, multicenter study in patients who are hospitalized ...

Phase

2.97 miles

Learn More »

BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies

This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with obinutuzumab in subjects with B-cell lymphoid malignancies.

Phase

3.49 miles

Learn More »